Fresensius Kabi USA, LLC
Código de etiquetadora NDC: 63323
¿Qué es una etiquetadora?
La empresa cuyo nombre aparece en el envase y en el directorio de códigos nacionales de medicamentos (NDC) de la FDA. Puede fabricar el medicamento o vender uno fabricado por otra empresa. La primera parte de cada código NDC identifica a la etiquetadora.
Solo datos oficiales de la FDA
Los productos, aprobaciones y retiros vienen de la FDA (directorio NDC, Drugs@FDA, informes de retiros). Los retiros se vinculan a esta empresa por el código NDC del producto retirado.
Si tiene preguntas sobre su medicamento, hable con su médico o farmacéutico. En una emergencia, llame al 911.
Medicamentos con receta
- PosaconazoleNoxafil · 1 producto
Solicitudes de la FDA de estos productos
- ANDA: Solicitud abreviada (ANDA): así se aprueba una versión genérica.
| Aprobada | Solicitud | Medicamento | Patrocinador |
|---|---|---|---|
| 26 de diciembre de 2023 | ANDA209983 | Posaconazole POSACONAZOLE | Fresenius Kabi USA |
El patrocinador es la empresa titular de la solicitud ante la FDA; puede ser distinta de la etiquetadora.
Cronología de retiros
2026
-
16 de julio de 2026 · Clase II · En curso · D-0727-2026 · Ropivacaine hydrochloride
Presence of Particulate Matter: Hair was found in products
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-0
-
16 de julio de 2026 · Clase II · En curso · D-0725-2026 · Glycopyrrolate
Presence of Particulate Matter: Hair was found in product
Glycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill in a 6.5 mL vial, Rx only, Multiple Dose Vials, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-578-05; NDC Vial: 63323-578-07
-
16 de julio de 2026 · Clase II · En curso · D-0726-2026 · Lidocaine
Presence of Particulate Matter: Hair was found in products
Lidocaine HCl Injection, USP, 2%, 100 mg per 5 mL (20 mg per mL), 25 Single Dose Vials, 5 mL per vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-208-05; NDC Vial: 63323-208-01
-
16 de julio de 2026 · Clase II · En curso · D-0728-2026 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
Presence of Particulate Matter: Hair was found in products
Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-485-27; NDC Vial: 63323-485-01
-
16 de julio de 2026 · Clase II · En curso · D-0729-2026 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
Presence of Particulate Matter: Hair was found in products
Xylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL), 25 Multiple-Dose Vials, 50 mL, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-485-57; NDC Vial: 63323-485-03
-
14 de mayo de 2026 · Clase III · En curso · D-0581-2026 · Epinephrine
Failed Impurities/Degradations Specifications
Epinephrine Injection, USP, 1mg/mL, 1 mL single-dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-696-02 (vial), NDC 63323-696-25 (carton)
-
11 de marzo de 2026 · Clase II · En curso · D-0424-2026 · Sodium chloride
Lack of Assurance of Sterility
0.45% Sodium Chloride Injection, USP, 1.125 grams per 250 mL (4.5 mg per mL), 250 mL in a 250 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Lake Zurich, IL 60047, Unit of Use NDC: 63323-626-03, Un
2025
-
6 de noviembre de 2025 · Clase I · En curso · D-0182-2026 · Famotidine
Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.
Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL vials, Rx only, Fresenius Kabi USA, LLC, NDC 63323-739-11 (unit of use), 63323-739-12 (unit of sale).
2022
-
22 de noviembre de 2022 · Clase II · Cerrado por la FDA · D-0127-2023 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 125 mg per 50 mL (2.5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-461-01), packaged in 25 Multiple Dose
-
22 de noviembre de 2022 · Clase II · Cerrado por la FDA · D-0129-2023 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose V
Mostrar los 44 retiros anteriores
2022
-
22 de noviembre de 2022 · Clase II · Cerrado por la FDA · D-0128-2023 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.5%, 250 mg per 50 mL (5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-463-01), packaged in 25 Multiple Dose Via
-
13 de abril de 2022 · Clase II · Cerrado por la FDA · D-1116-2022 · Propofol
cGMP deviations: Temperature abuse
Diprivan (Propofol) Emulsion, 200 mg per 20 mL (10mg/mL), 20 mL vial, Rx only, MFG: App Pharmaceutical LLC, NDC 63323-269-29
-
13 de abril de 2022 · Clase II · Cerrado por la FDA · D-1052-2022 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
cGMP deviations: Temperature abuse
Xylocaine + Epinephrine, multi dose vial 1%, packaged in a) 20 mL, 25-count box (NDC 63323-482-27) b) 50 mL, 25-count box (NDC 63323-482-57), Rx only, MFG: Fresenius Kabi USA LLC
-
13 de abril de 2022 · Clase II · Cerrado por la FDA · D-1115-2022 · Propofol
cGMP deviations: Temperature abuse
Diprivan (Propofol) Emulsion, 100 mg/mL, 10mL vial, Rx only, MFG: App Pharmaceutical LLC, NDC 63323-269-10
-
13 de abril de 2022 · Clase II · Cerrado por la FDA · D-1053-2022 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
cGMP deviations: Temperature abuse
Xylocaine + Epinephrine, multi dose vial 2%, 20 mL, 25 count box, Rx only, MFG: Fresenius Kabi USA LLC, NDC 63323-483-27
-
4 de marzo de 2022 · Clase I · Cerrado por la FDA · D-0750-2022 · Sodium acetate
Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.
Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20 vials per shipper (NDC 63323-032-00), each vial: 100 mL fill in a 100 mL vial (NDC 63323-032-04), Rx Only, Fresenius Kabi, Lake Zuri
2021
-
17 de septiembre de 2021 · Clase II · Cerrado por la FDA · D-0856-2021 · Morphine sulfate
Defective container: Cracked vials leading to lack of sterility assurance
Morphine Sulfate Injection, USP, 2 mg per mL, 1 mL single dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-452-01. 25 vials per tray packaged 18 trays per shipper
-
25 de junio de 2021 · Clase II · Cerrado por la FDA · D-0651-2021 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
Low out of specification results for epinephrine assay.
Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose Vial, 25 Vials per Tray, Rx only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047.
2020
-
23 de diciembre de 2020 · Clase I · Cerrado por la FDA · D-0245-2021 · Ketorolac tromethamine
Presence of Particulate Matter - found in reserve sample vials at the firm.
Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single Dose Vials (NDC 63323-162-00); 25 x 1 mL Single Dose Vials per tray (NDC 63323-162-01); For IM or IV use, Rx only, Fresenius Kabi, Lake Zurich,
-
17 de diciembre de 2020 · Clase II · Cerrado por la FDA · D-0184-2021 · Ketorolac tromethamine
Presence of Particulate Matter - found in reserve sample vials at the firm.
Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), packaged in 2 mL Single Dose Vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-162-02
-
10 de diciembre de 2020 · Clase II · Cerrado por la FDA · D-0172-2021 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Subpotent Drug: Low out-of-specification assay results for the epinephrine component.
Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP), 0.5%, 150 mg per 30 mL (5 mg per mL), 30 mL Single Dose Vial (NDC 63323-462-01), packaged as 25 Single Dose Vials per tray (NDC 63323-462-37), Rx only, Fr
-
17 de noviembre de 2020 · Clase III · Cerrado por la FDA · D-0105-2021 · Doxorubicin hydrochloride
Cross Contamination with Other Products: trace amounts of octreotide found during testing
DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05
-
13 de julio de 2020 · Clase III · Cerrado por la FDA · D-1391-2020 · Fosaprepitant
Labeling Error: Label Error on Declared Strength: Carton label and product insert incorrectly states the quantity of the excipient edetate disodium (EDTA) as 5.4 mg / vial, rather than the actual amount of 18.8 mg / vial.
Fosaprepitant for Injection, 150 mg / vial in a 10 mL Single-Dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047; NDC 63323-972-10
-
17 de junio de 2020 · Clase III · Cerrado por la FDA · D-1392-2020 · Famotidine
TEMPERATURE ABUSE: Complaint received from customer that product was received in a non-refrigerated state.
Famotidine Injection, USP, 20 mg/2mL, 2 mL vial, Rx only, Single Dose Vial, For Intravenous Use Only After Dilution, Distributed by HF Acquisition Co, LLC, Mukilteo, WA 98275, NDC 63323-739-12
-
20 de abril de 2020 · Clase I · Cerrado por la FDA · D-1296-2020 · Ketorolac tromethamine
Presence of Particulate Matter - found in reserve sample vials at the firm.
Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single Dose Vials (NDC 63323-162-00); 25 x 1 mL Single Dose Vials per tray (NDC 63323-162-01); For IM or IV use, Rx only, Fresenius Kabi, Lake Zurich,
-
20 de abril de 2020 · Clase II · Cerrado por la FDA · D-1297-2020 · Ketorolac tromethamine
Presence of Particulate Matter - found in reserve sample vials at the firm.
Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), packaged in 2 mL Single Dose Vials (NDC 63323-162-03), 25 x 2 mL Single Dose Vials per tray (NDC 63323-162-02); For IM use only, Not for IV use, Rx on
2019
-
28 de junio de 2019 · Clase I · Cerrado por la FDA · D-1489-2019 · Fluorouracil
Presence of Particulate Matter; glass particulates
Fluorouracil Injection, USP, 5 g / 100 mL (50 mg / mL), 100 mL fill in a 100 mL vial, Rx Only, Mfd. by: Fresenius Kabi, Lake Zurich, IL 60047. 63323-117-61 [Fresenius Kabi brand] and NDC 63323-117-69 [NOVAPLUS brand]
-
22 de mayo de 2019 · Clase III · Cerrado por la FDA · D-1386-2019 · Ondansetron
Failed Impurities/Degradation Specifications.
Ondansetron Injection, USP, 40 mg / 20 mL, 20 mL vial, Rx Only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047, NDC 63323-374-20
2018
-
15 de noviembre de 2018 · Clase I · Cerrado por la FDA · D-0298-2019 · Sodium chloride
Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620 indicating that the stoppers do not contain natural rubber latex. The tray label for these two product codes and the vial label for product code 918620 also inc
SODIUM CHLORIDE INJECTION, USP, 0.9%, 10 mL Single Dose Vial, packaged in a 25-unit tray, Rx Only, APP Pharmaceuticals, LLC Schaumburg, IL 60173. NDC 63323-186-10 Product code 918610
-
15 de noviembre de 2018 · Clase I · Cerrado por la FDA · D-0299-2019 · Sodium chloride
Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620 indicating that the stoppers do not contain natural rubber latex. The tray label for these two product codes and the vial label for product code 918620 also inc
SODIUM CHLORIDE INJECTION, USP, 0.9%, 20 mL Single Dose Vial, packaged in a 25-unit tray, Rx Only, APP Pharmaceuticals, LLC Schaumburg, IL 60173. NDC 63323-186-20, Product code 918620
2017
-
8 de marzo de 2017 · Clase II · Cerrado por la FDA · D-0668-2017 · Hydralazine hydrochloride
Temperature Abuse: Certain pieces of these lots distributed by McKesson Medical Surgical Inc. were inadvertently stored refrigerated rather than the labeled room temperature recommendation.
hydrALAZINE HYDROCHLORIDE INJECTION, USP, 20 mg/mL, 1 mL Single Dose Vial, packaged in 25 Vials per carton, Rx only, APP Fresenius Kabi USA, LLC, Lake Surich, IL 60047, NDC 63323-614-01, Distributed by McKesson Medical-S
2016
-
16 de diciembre de 2016 · Clase II · Cerrado por la FDA · D-0456-2017 · Midazolam
Failed Impurities/Degradation Specifications
MIDAZOLAM INJECTION, USP, *25 mg/5 mL, (5 mg/ mL), 5 mL vials, 10 Vials per carton, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173 --- NDC 63323-412-05
-
25 de abril de 2016 · Clase II · Cerrado por la FDA · D-1037-2016 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Presence of Particulate Matter: Glass particulate found in sterile injectable product
Sensorcaine- MPF (Bupivacaine HCI Injection, USP), 0.75% in a 30 mL Single Dose Vial, Rx only, Fresenius Kabi USA LLC, Lake Zurich, IL 60047, NDC 63323-472-37
-
7 de abril de 2016 · Clase III · Cerrado por la FDA · D-0818-2016 · Haloperidol decanoate
Failed Impurities/Degradation Specifications: Firm is recalling product due to an impurity out-of-specification result.
Haloperidol Decanoate Injection, 50 mg/mL, 1 mL vial, Rx Only. Fresenius Kabi USA LLC, Lake Zurich, IL 60047, NDC 63323-469-01.
-
5 de abril de 2016 · Clase II · Cerrado por la FDA · D-0819-2016 · Cisatracurium besylate
Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Preservative free on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.
Cisatracurium Besylate Injection, 20 mg per 10 mL (2 mg per mL), For intravenous injection, 10 mL Multiple Dose Vial, Rx only, Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-417-10
2015
-
28 de julio de 2015 · Clase III · Cerrado por la FDA · D-1327-2015 · Hydralazine hydrochloride
Incorrect Expiration Date: The "11/06" expiration date printed on the tray (secondary packaging) is incorrect (it should be 11/2016)
Hydralazine Hydrochloride Injection, USP, 20 mg/mL, 1 mL fill, in a 2 mL; single dose vial. Manufactured by Fresenius Kabi USA 2020 N Ruby Street, Melrose Park, IL 60160-1112 for Fresenius Kabi USA, 3 Corporate Dr Lake Z
-
4 de junio de 2015 · Clase II · Cerrado por la FDA · D-1234-2015 · Rifampin
Failed Impurities/Degradation Specifications; out-of-specification for color, impurity, and degradation
Rifampin for Injection, USP 600mg/vial in a 20mL vial, Rx only, Manufactured for Fresenius Kabi LLC 3 Corporate Drive, Lake Zurich, IL, 60047, by Fresenius Kabi LLC, 2020 N Ruby Street, Melrose Park, IL 60160. NDC 63323-
-
28 de abril de 2015 · Clase II · Cerrado por la FDA · D-1114-2015 · Dextrose, soybean oil, electrolytes, lysine, phenylalanine, leucine, valine, threonine, methionine, isoleucine, tryptophan, alanine, arginine, glycine, proline, histidine, glutamic acid, serine, aspartic acid and tyrosine
Labeling: Label Error on Declared Strength: Labeled 3.1% Amino Acids but contains 3.3% Amino Acids
KABIVEN [(3.9%) Lipid Injectable Emulsion with (3.1%) Amino Acids and Electrolytes and (9.8%) Dextrose; Sulfite-free], Rx Only. Manufactured by: FRESENIUS KABI Uppsala, Sweden. Packaged in 1) 1,540 mL Bags, NDC: 63323-71
2014
-
12 de noviembre de 2014 · Clase II · Cerrado por la FDA · D-0290-2015 · Gentamicin sulfate
Defective Container: Vials may be missing stoppers.
GENTAMICIN INJECTION, USP, equivalent to 40 mg/mL, Rx only, 20 mL Multiple Dose Vial, Manufactured by APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-010-20
-
13 de agosto de 2014 · Clase II · Cerrado por la FDA · D-1545-2014 · Propranolol hydrochloride
CGMP Deviations: Citations given to API supplier by the Italian Health Agency AIFA for several critical deficiencies which caused a recall of the API lot used to manufacture Propanolo HCl Injection.
PROPRANOLOL HYDROCHLORIDE INJECTION, USP 1 mg/mL, 1 mL Single Dose Vial, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173, NDC 63323-604-01
-
2 de mayo de 2014 · Clase II · Cerrado por la FDA · D-1429-2014 · Fosphenytoin sodium
Presence of Particular Matter: Potential glass delamination and consistent with glass particulates observed in sample vials.
Fosphenytoin Sodium Injection, USP, 500 mg PE/10 mL (50 mg PE/mL), (PE= phenytoin sodium equivalents) 10 mL Single Use Vial, Rx only, Manufactured for APP Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-403-10
-
2 de mayo de 2014 · Clase II · Cerrado por la FDA · D-1428-2014 · Fosphenytoin sodium
Presence of Particular Matter: Potential glass delamination and consistent with glass particulates observed in sample vials.
Fosphenytoin Sodium Injection, USP, 100 mg PE/2 mL (50 mg PE/mL) (PE= phenytoin sodium equivalents) 2 mL Single Use Vial, Rx only, Manufactured for APP Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-403-02
-
14 de abril de 2014 · Clase III · Cerrado por la FDA · D-0247-2015 · Haloperidol decanoate
Failed Impurities/Degradation Specifications: Fresenius Kabi is recalling three lots of Haloperidol Decanoate Injection due to an out-of-specification result.
HALOPERIDOL DECANOATE INJECTION, 50 mg/mL, 1 mL vial, Rx only, Fresenius Kabi USA, LLC, Schaumburg, IL 60173 NDC 63323-469-01
-
22 de enero de 2014 · Clase II · Cerrado por la FDA · D-1148-2014 · Heparin sodium
Subpotent; 18 month time point
Heparin Sodium Injection, USP 10,000 USP units per 10 mL (1,000 USP units per mL) For IV or SC use, Multi-Dose Vial, Rx only, NDC 63323-540-11, 25 vials in tray, each boxed vial individually labeled as: Heparin Sodium In
2013
-
6 de diciembre de 2013 · Clase III · Cerrado por la FDA · D-379-2014 · Folic acid
Failed Impurities/Degradation specifications: out-of-specification results 14 & 15 month time point
FOLIC ACID INJECTION, USP; 5 mg/mL ; For IM, IV or SC Use; 10 mL; Multiple Dose Vial; Rx only; APP Pharmaceuticals, LLC; Schaumburg, IL 60173 NDC 63323-184-11
-
8 de noviembre de 2013 · Clase III · Cerrado por la FDA · D-016-2014 · Paclitaxel
Labeling: Incorrect or Missing Package Insert- Missing text on the product insert in the "Clinical Studies" and "Specific Adverse Events" sections.
PACLITAXEL INJECTION, USP (semisynthetic); 300 mg/50 mL; (6 mg/mL); Multiple Dose Vial;(NDC 63323-763-50); Rx Only; Manufactured for APP Pharmaceuticals, LLC; Schaumburg, IL 60173; Made in India
-
1 de julio de 2013 · Clase II · Cerrado por la FDA · D-685-2013 · Benztropine mesylate
Presence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination observed in reserve sample vials
Benztropine Mesylate Injection, USP, 2 mg/2 mL (1 mg/1 mL), 2 mL Single Dose Vial, Rx only, labeled as a) Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-970-02; and b) Manufactured in the USA
-
24 de junio de 2013 · Clase II · Cerrado por la FDA · D-804-2013 · Oxytocin
Subpotent Drug; 15-month stability test station
Oxytocin Injection, USP, (Synthetic), 10 USP Units/mL, for IV Infusion or IM Use, Rx Only, 1 mL vial, APP ) 10 USP Units/mL, 1 mL, APP Pharmaceuticals, LLC Schaumburg, IL, 60173, NDC 63323-012-01.
-
25 de mayo de 2013 · Clase I · Cerrado por la FDA · D-920-2013 · Magnesium sulfate heptahydrate
Presence of Particulate Matter: Glass particulate matter was observed in a retention sample during an annual review.
Magnesium Sulfate Injection, USP, 50% (25 grams/50 mL), For IM or IV Use, 50 mL, Single Dose Vial, Rx only, Preservative Free, APP Pharmaceuticals, LLC, Schaumburg, IL, 60173, NDC 63323-064-50
-
21 de mayo de 2013 · Clase III · Cerrado por la FDA · D-688-2013 · Folic acid
Failed Impurities/Degradation Specification
Folic Acid Injection, USP, 5 mg/mL, For IM, IV or SC Use, 10 mL, Multiple Dose Vial, Rx only, APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-184-11
-
22 de enero de 2013 · Clase II · Cerrado por la FDA · D-915-2013 · Irinotecan hydrochloride
Crystallization: Active pharmaceutical ingredient is precipitating in product solution.
IRINOTECAN HYDROCHLORIDE INJECTION, 40 mg/2 mL (20 mg/mL), 2 mL Single Dose Vial, Rx only, Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-193-02, UPC 3 63323 19302 7.
2012
-
27 de septiembre de 2012 · Clase II · Cerrado por la FDA · D-0296-2015 · Ondansetron
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
ONDANSETRON INJECTION, USP, 4 mg/ 2 mL (2 mg/mL), For IM or IV Use, Single Dose 2 mL Vials, Rx only. APP Pharmaceuticals, LLC, Schaumburg, IL 60173. NDC: 63323-373-02
-
27 de septiembre de 2012 · Clase II · Cerrado por la FDA · D-0297-2015 · Cyanocobalamin
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
CYANOCOBALAMIN INJECTION, USP, 1000 mcg/mL, For IM or IV Use, Multiple Dose 2 mL Vials, Rx only. APP Pharmaceuticals, LLC, Schaumburg, IL 60173. NDC: 63323-044-01.
-
27 de septiembre de 2012 · Clase II · Cerrado por la FDA · D-0295-2015 · Midazolam
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
MIDAZOLAM HYDROCHLORIDE INJECTION, 5 mg/1 mL, C-IV, For IM or IV Use, 2 mL Vials, Rx only. APP Pharmaceuticals, LLC. Schaumburg, IL 60173. NDC: 63323-412-25.
¿Qué significan las clases de retiro?
Clase I: El tipo más grave: existe una probabilidad razonable de que usar el producto cause problemas de salud graves o la muerte.
Clase II: Usar el producto puede causar problemas de salud temporales o reversibles con tratamiento, o la probabilidad de problemas graves es remota.
Clase III: No es probable que usar el producto cause problemas de salud (por ejemplo, un problema de etiquetado o de envase).
Siguientes pasos
- Encuentre una farmacia cerca de ustedPregunte qué empresa fabricó su medicamento y si tiene un retiro
- Últimos retiros de medicamentos de la FDATodas las empresas, los más recientes primero
- Todas las empresas farmacéuticasDe la A a la Z
- Todos los medicamentos con receta de la A a la ZBusque por nombre genérico, de marca o en español
Fuentes
- NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026
Buscador de informes de retiros de la FDA → · Informar un error →